Mizolastine
From Wikipedia, the free encyclopedia
 |
|
|
Mizolastine
|
|
| Systematic (IUPAC) name | |
| 2-[ [1-[1-[(4-fluorophenyl)methyl]benzimidazol-2-yl]piperidin-4-yl]-methylamino]-3H-pyrimidin-4-one | |
| Identifiers | |
| CAS number | |
| ATC code | R06 |
| PubChem | |
| Chemical data | |
| Formula | C24H25FN6O |
| Mol. mass | 432.493 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Mizolastine is a once daily, non-sedating antihistamine. Sold in the UK on prescriptions as Mizollen. It blocks histamine H1 receptors and is commonly fast-acting. It does not prevent the actual release of histamine from mast cells, just prevents it binding to receptors. Side effects can include dry mouth and throat. May also result, in some patients, in dream disturbance or enhancement - this despite not causing drowsiness nor passing into the brain.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
Mechanism of action:
Characteristics of Mizolastine
|
|||||||||||||||||||||||||||||
